Literature DB >> 12088725

In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors.

Roberto La Bella1, Elisa Garcia-Garayoa, Michael Langer, Peter Bläuenstein, Annette G Beck-Sickinger, P August Schubiger.   

Abstract

A new radiolabeled bombesin analogue, [99mTc(I)-PADA-AVA]bombesin (7-14), was synthesized and in vitro and in vivo characterized. High affinity and rapid internalization were obtained in binding assays. A specific binding towards gastrin releasing peptide receptors-positive tissues, pancreas and tumor, was observed in CD-1 nu/nu mice bearing PC-3 prostate adenocarcinoma xenografts. We therefore conclude that [99mTc(I)-PADA-AVA]bombesin (7-14) might have promising characteristics for applications in nuclear medicine, namely for diagnosis of GRP receptor overexpressing tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088725     DOI: 10.1016/s0969-8051(02)00314-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  13 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 3.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

4.  DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.

Authors:  Hanwen Zhang; Jochen Schuhmacher; Beatrice Waser; Damian Wild; Michael Eisenhut; Jean Claude Reubi; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-30       Impact factor: 9.236

5.  Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors.

Authors:  Nicole F Steinmetz; Amber L Ablack; Jennifer L Hickey; Jailal Ablack; Bhavik Manocha; Joe S Mymryk; Leonard G Luyt; John D Lewis
Journal:  Small       Date:  2011-04-26       Impact factor: 13.281

6.  99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor.

Authors:  Stephanie R Lane; Bhadrasetty Veerendra; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Silvia S Jurisson; Charles J Smith
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

7.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

8.  Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.

Authors:  Alexander Sturzu; Sumbla Sheikh; Hartmut Echner; Thomas Nägele; Martin Deeg; Bushra Amin; Christian Schwentner; Marius Horger; Ulrike Ernemann; Stefan Heckl
Journal:  Invest New Drugs       Date:  2013-06-01       Impact factor: 3.850

Review 9.  Radiolabelled peptides for oncological diagnosis.

Authors:  Peter Laverman; Jane K Sosabowski; Otto C Boerman; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 10.  Targeting prostate cancer with radiolabelled bombesins.

Authors:  Theodosia Maina; Berthold Nock; Stephen Mather
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.